Glenmark Pharma shares hit 10% upper ciruit on $ 700 mn cancer drug deal

Glenmark Pharma shares hit a 10% upper circuit and a new 52-week high of ₹2,095.65 on the BSE after its subsidiary, Ichnos Glenmark Innovation, signed a global licensing pact with AbbVie for experimental cancer drug ISB 2001, valued at up to $700 million.